Previous 10 | Next 10 |
Regeneron Pharmaceuticals (NASDAQ: REGN ) announces the successful outcome of a Phase 3 clinical trial, ELIPSE HoFH , evaluating evinacumab in patients with an inherited form of severely elevated levels of "bad" (LDL-C) cholesterol called homozygous familial hypercholesterolemia (HoFH). ...
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (“Novelion” or the “Company...
VANCOUVER, British Columbia, July 16, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced ...
VANCOUVER, British Columbia, July 05, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, announced that on July 3, 2019, the C...
VANCOUVER, British Columbia, June 24, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced ...
Gainers: CIRCOR International, Inc. (NYSE: CIR ) +41% . JMU Limited (NASDAQ: JMU ) +39% . Westwater Resources, Inc. (NASDAQ: WWR ) +21% . Biocept, Inc. (NASDAQ: BIOC ) +22% . Sesen Bio, Inc. (NASDAQ: SESN ) +21% . OncoSec Medical Incorporated (NASDAQ: ONCS ) +20% . Dycom Indust...
Novelion Therapeutics' (NASDAQ: NVLN ) wholly-owned subsidiary Aegerion Pharmaceuticals has entered into a plan funding agreement (PFA) and a restructuring support agreement (RSA) that will result in selling 100% of its reorganized stock to, and becoming a wholly-owned subsidiary of, Dublin-...
Transaction is result of comprehensive capital structure and strategic review conducted independently by both Novelion’s and Aegerion’s Boards of Directors Aegerion will continue to make available to patients its two approved therapies, JUXTAPID ® and MYALEPT ® ...
Novelion Therapeutics (NASDAQ: NVLN ): Q1 Non-GAAP EPS of $0.10 misses by $0.05 ; GAAP EPS of -$1.67. More news on: Novelion Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “...
News, Short Squeeze, Breakout and More Instantly...
Novelion Therapeutics Inc. Company Name:
NVLN Stock Symbol:
NASDAQ Market:
Novelion Therapeutics Inc. Website:
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that on October 7, 2019 the Nasdaq Office of General Counsel notified the Company that the Nasd...
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) today announced that it has filed its notice of meeting and definitive proxy statement with the applicable...
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated September 11, 2019, the acquisition by Amryt Pharma Pl...